Synthesis of Barbituric and Thiobarbituric Acids Bearing 5,6-Diphenyl-1,2,4-Triazin-3-yl Moiety as CDK2 Inhibitors of Tumor Cells
American Journal of Heterocyclic Chemistry
Volume 5, Issue 4, December 2019, Pages: 76-80
Received: Aug. 27, 2019; Accepted: Sep. 10, 2019; Published: Oct. 11, 2019
Views 42      Downloads 15
Author
Dina Abed Bakhotmah, Department of Chemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
Article Tools
Follow on us
Abstract
Synthesis of several new diphenyl-1',2',4'-triazin-3'-yl barbituric acid are described. The method involves addition reaction of isocyanate and isothiocyanate and 3-amino-5,6-diphenyl-1,2,4-triazine (1) to give N1,N3-disubstituted urea 2 and N1,N3-disubstituted thioureas 3 and 4 respectively. Further, ring closure reactions with malonate ester give barbituric acid 5 and thiobarbituric acid 6 and 7. The Presence of the active methylene in the skeleton of compound 5-7 at C-5 are deduced by condensation with pyridine-4-carboxyladehyde to give barbituric and thiobarbituric acids (8-10). Further fluoroacylation of compounds 5-7, afforded 1-(cyclohexyl/methyl/phenyl)-3-(5',6'-diphenyl-1',2',4'-triazin-3'-yl)-5-(trifluoracetyl)-5H-barbituric/thiobarbituric acids (11-13). Synthesis compounds of the series 5-(trifluoroacetyl) barbituric acid (11) and 5-(trifluoroacetyl) thiobarbituric acids (12 and 13) were able to inhibit activity of CDK2 in a biochemical assay with IC50 values comparable to olomoucine. In addition, a pyridine side chain at C-5 (compound 9 and 10) significantly decreases CDK2 inhibitory activity.
Keywords
Barbituric, Thiobarbituric, 1,2,4-triazine, CDK2, Malonate Ester, Trifluoroacylation
To cite this article
Dina Abed Bakhotmah, Synthesis of Barbituric and Thiobarbituric Acids Bearing 5,6-Diphenyl-1,2,4-Triazin-3-yl Moiety as CDK2 Inhibitors of Tumor Cells, American Journal of Heterocyclic Chemistry. Vol. 5, No. 4, 2019, pp. 76-80. doi: 10.11648/j.ajhc.20190504.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
C. Schiffer, (2007). BCR-ABL tyrosine kinase inhibitors for chronic myeloge-nous leukemia. N. Engl. J. Med. 357, 258-265.
[2]
P. Cohen, (2002). Protein kinases—the major drug targets of the twenty-firstcentury? Nat. Rev. Drug Discov. 1, 309–315.
[3]
V. Miduturu, X. Deng, N. Kwiatkowski, W. Yang, L. Brault, P. Filippakopoulos, E. Chung, Q. Yang, J. Schwaller, S. Knapp, R. King, J. Lee, S. Herrgard, P. Zarrinkar, N. Gray, (2011). High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors, Chemistry & Biology, 18 (7), 868-879, doi.org/10.1016/j.chembiol.2011.05.010.
[4]
B. Mathew, J. Suresh, D. Vinod., (2012). Antitumor activity of 5-[(2E)-1-(1H-benzimidazol-2-yl)-3-substituted-phenylprop-2-en-1-ylidene]pyrimidine2,4,6(1H,3H,5H)-triones against Dalton’s ascetic lymphoma in mice. Med Chem Res 22: 3911-3917.
[5]
T. Venkatesh, Y. Bodke, R. Kenchappa and S. Venkatesh, (2016). Synthesis, Antimicrobial and Antioxidant Activity of Chalcone Derivatives Containing Thiobarbitone Nucleus. Med chem (Los Angeles), 6 (7), 440-448. DOI: 10.4172/2161-0444.1000383.
[6]
D. Bakhotmah, R. Abdel-Rahman, (2016), A Review on the Synthesis and Chemistry of Bioactive Pyrazolines Bearing 1,2,4-Triazine Moieties, Mini-Reviews in Organic Chemistry, 13, 62-77. 13 (1): 62-77.
[7]
R. Abdel-Rahman, M. Makki, T. Ali, M. Ibrahim, (2015), 1,2,4-Triazine chemistry Part IV: Synthesis and chemical behavior of 3-functionalized 5,6-diphenyl-1,2,4-triazines towards some nucleophilic and electrophilic reagents, J. Heterocyclic chem. 52: 1595-1607.
[8]
A. Bazgir, M. Khanaposhtani and A. Soorki, (2008), One-pot synthesis and antibacterial activities of pyrazolo[4',3':5,6]pyrido[2,3-d]pyrimidine-dione derivatives. Bioorganic and medicinal chemistry letters, 18, 5800-5803.
[9]
M. Masoud, M. Awad, M. Shaker, M. El-Tahawy, (2010), The role of structural Chemistry in the inhibitive performance of some aminopyrimidines on the corrosion of steel, Corrosion Science, 52 (7), 2387-96.
[10]
R. Abdel-Rahman, M. Makki, M. Ali, M. Ibrahim, (2013), 1,2,4-Triazine Chemistry Part III: Synthetic Strategies to Functionalized Bridgehead Nitrogen Heteroannulated 1,2,4-Triazine Systems and Their Regiospecific and Pharmacological Properties. Current Organic Chemistry, 10, 136-160.
[11]
R. Abdel-Rahman, K. El-mahdy, (2012), Biological Evaluation of Pyramidpyrimidines as Multi-Targeted Small Molecule Inhibitors and Resistance Modifying Agents. Heterocycles, 85, 2391-2414. doi.org/10.3987/REV-12-745.
[12]
B. Vinosha, S. Perumal, S. Renuga, A. Almansour, (2012) A facile domino protocol for the stereoselective synthesis of trans-2,3-dihydrobenzofurans and cis-5, 6-dihydrofuro[2,3-d]pyrimidines, Tetrahedron Letters, 53, 962-966.
[13]
L. Ma, S. Li, H. Zheng, J. Chen, L. Lin, X. Ye, Z. Chen, Q. Xu, T. Chen and J. Yang, (2011), Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease. European journal of medicinal chemistry, 46 (6): 2003-10. doi: 10.1016/j.ejmech.2011.02.033.
[14]
M. Palmer, P. Preston and M. F. Stevens, The Mass Spectra of 1,2,4-Triazines and Related Compounds. Organic Mass Spectrometry Organic Mass Spectrometry 1971, 5, 1085-1092.
[15]
J. Hunt, T. Mitt, R. Borzilleri, J. Gullo-Brown, J. Fargnoli, B. Fink, W. C Han, S. Mortillo, G. Vite, B. Wautlet, T. Wong, C. Yu, X. Zheng, R. Bhide, (2004) Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template. J Med Chem 47 (16): 4054-9.
[16]
T. Gucky, E. Řezníčková, P. Dzubak, Hajduch, K. Marian, (2010). ChemInform Abstract: Synthesis and Anticancer Activity of Some 1,5-Diaryl-3-(3,4,5-trihydroxyphenyl)-1H-pyrazolo[4,3-e][1,2,4]triazines, Monatsh Chem., 141: 709-714. 10.1007/s00706-010-0314-4.
[17]
A. Senderowicz, Inhibitors of cyclin-dependent kinase modulators for cancer therapyProgress in Drug Research (2005), Progress in Drug Research. 63, 183-206.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186